Observational studyBiomarkers in medicine2022
Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients.
Observational study in Biomarkers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Prognostic models in COVID-19 infection that predict severity: a systematic review.European journal of epidemiology · 2023Pooled it
- Morphological Changes in the Placenta of Patients with COVID-19 During Pregnancy.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Neurological Sequelae of Post-COVID-19 Fatigue: A Narrative Review of Dipeptidyl Peptidase IV-Mediated Cerebrovascular Complications.Current issues in molecular biology · 2024Review
- ACE2, ACE, DPPIV, PREP and CAT L enzymatic activities in COVID-19: imbalance of ACE2/ACE ratio and potential RAAS dysregulation in severe cases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.Future virology · 2023Review
- Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives mInternational journal of oncology · 2023Article
- Rebound increase in circulating dipeptidyl peptidase 4 (DPP4) enzyme activity after acute COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Reply to Firneisz: "Rebound increase in circulating dipeptidyl peptidase-4 (DPP4) enzyme activity after acute Covid-19".Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology.Biomedicines · 2022Review
- Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone.Biomedicines · 2022Article
- Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.